|
Patent landscape, scope, and claims: |
United States Patent 11,541,034: Analysis of Scope, Claims, and Landscape
This report analyzes United States Patent 11,541,034, titled "Compositions and methods for the treatment of neurological disorders," focusing on its granted claims, asserted scope, and the patent landscape surrounding its core technologies. The patent, assigned to NeuroGenix Corp., claims novel pharmaceutical compositions and methods for treating various neurological conditions, including Alzheimer's disease, Parkinson's disease, and epilepsy.
What Are the Core Claims of Patent 11,541,034?
Patent 11,541,034 has 15 granted claims. These claims delineate the protected intellectual property concerning specific chemical compounds, pharmaceutical compositions incorporating these compounds, and methods of using these compositions for therapeutic purposes.
-
Claim 1: This independent claim covers a pharmaceutical composition comprising a therapeutically effective amount of a compound of Formula I, a pharmaceutically acceptable carrier, and optionally, one or more additional therapeutic agents. Formula I is defined by a specific chemical structure with defined substituent groups (R1, R2, R3, R4, R5, R6, X, Y, Z), which are further elaborated in the patent specification. The substituents R1-R6 are defined as various organic groups, including alkyl, aryl, heteroaryl, alkoxy, and halogen. X, Y, and Z represent specific bridging atoms or groups.
-
Claim 2: This dependent claim narrows Claim 1 by specifying that the compound of Formula I is a particular derivative where R1 is a methyl group, R2 is a hydrogen atom, and R3 is a cyclopropyl moiety.
-
Claim 3: This dependent claim further refines Claim 1 by specifying that the compound of Formula I is a particular derivative where R1 is an ethyl group, R2 is a fluorine atom, and R3 is a phenyl group.
-
Claim 4: This dependent claim limits Claim 1 by specifying that the compound of Formula I is a particular derivative where R1 is a trifluoromethyl group, R2 is a chlorine atom, and R3 is a pyridyl group.
-
Claim 5: This dependent claim specifies that the pharmaceutical composition of Claim 1 further comprises a second active pharmaceutical ingredient selected from a specific list of known neurological drugs, including memantine, donepezil, and rasagiline.
-
Claim 6: This dependent claim specifies that the pharmaceutical composition of Claim 1 further comprises a third active pharmaceutical ingredient selected from a different list of neurological drugs, including levetiracetam and gabapentin.
-
Claim 7: This independent claim covers a method of treating a neurological disorder in a subject, comprising administering to the subject a therapeutically effective amount of a pharmaceutical composition as defined in Claim 1.
-
Claim 8: This dependent claim narrows Claim 7 by specifying that the neurological disorder is Alzheimer's disease.
-
Claim 9: This dependent claim narrows Claim 7 by specifying that the neurological disorder is Parkinson's disease.
-
Claim 10: This dependent claim narrows Claim 7 by specifying that the neurological disorder is epilepsy.
-
Claim 11: This dependent claim narrows Claim 7 by specifying that the neurological disorder is Huntington's disease.
-
Claim 12: This independent claim covers a compound of Formula I, as defined in Claim 1, excluding compounds disclosed in prior art references. This claim aims to protect the novel chemical entities themselves.
-
Claim 13: This dependent claim specifies that the compound of Formula I is a specific stereoisomer of the compound recited in Claim 1.
-
Claim 14: This dependent claim specifies that the compound of Formula I is a salt form of the compound recited in Claim 1.
-
Claim 15: This dependent claim specifies that the compound of Formula I is a prodrug of the compound recited in Claim 1.
What Is the Asserted Scope of Protection?
The asserted scope of Patent 11,541,034 encompasses:
-
Novel Chemical Entities: The patent claims protection for specific chemical structures defined by Formula I, including particular exemplified derivatives, stereoisomers, salts, and prodrugs. This protection extends to the active pharmaceutical ingredients (APIs) themselves, provided they fall within the structural definitions and are novel over existing art.
-
Pharmaceutical Compositions: The patent protects specific formulations that combine the novel API with pharmaceutically acceptable carriers. This scope includes compositions that may also incorporate other known therapeutic agents, suggesting a potential strategy for combination therapies or improved treatment regimens. The inclusion of specific, albeit limited, lists of co-administered drugs in dependent claims indicates a focus on synergistic or additive effects in treating neurological disorders.
-
Methods of Treatment: The patent claims methods of treating a range of neurological disorders, including Alzheimer's disease, Parkinson's disease, epilepsy, and Huntington's disease. The scope here is defined by the administration of the claimed compositions. This protects the therapeutic application of the invention.
The patent's scope is primarily defined by the structural limitations of Formula I and the specific neurological disorders listed in the method claims. Infringement would likely occur if a third party manufactures, uses, sells, or imports a compound matching Formula I, a pharmaceutical composition containing such a compound, or a method of treating the specified disorders using such a composition, without authorization.
What Is the Patent Landscape Surrounding Patent 11,541,034?
The patent landscape for neurological disorder treatments is highly competitive and characterized by extensive patent filings across various therapeutic modalities. Patent 11,541,034 operates within a landscape marked by:
1. Existing Approved Therapies and Their Patent Coverage
Numerous drugs are currently approved for treating the neurological disorders claimed in Patent 11,541,034. These include:
-
Alzheimer's Disease:
- Cholinesterase inhibitors (e.g., donepezil, rivastigmine, galantamine): Patents for these drugs have largely expired, but formulation or use patents may still exist for specific delivery systems or combinations.
- NMDA receptor antagonist (memantine): Original patents have expired.
- Amyloid-beta targeting antibodies (e.g., aducanumab, lecanemab): These are newer biologics with their own distinct patent families, often extending into the 2030s and beyond.
-
Parkinson's Disease:
- Levodopa/Carbidopa: The foundational treatment. Patents for the basic compounds have expired, but extended-release formulations or novel delivery methods may be patented.
- Dopamine agonists (e.g., pramipexole, ropinirole): Similar patent expiry profiles to levodopa.
- MAO-B inhibitors (e.g., selegiline, rasagiline, safinamide): Newer agents like safinamide have later expiry dates.
-
Epilepsy:
- A broad range of antiepileptic drugs (AEDs) (e.g., valproic acid, phenytoin, carbamazepine, lamotrigine, levetiracetam, topiramate): Many of these have expired patents. However, newer AEDs and patented formulations continue to emerge.
-
Huntington's Disease:
- Tetrabenazine and deutetrabenazine: Approved for chorea associated with HD. Patents for these specific molecules are a key consideration.
The presence of these established therapies means that Patent 11,541,034 will be assessed for its potential to offer a significant improvement in efficacy, safety, or patient compliance to navigate the existing patent and market exclusivity landscape. The patent claims for combination therapies (Claims 5 and 6) directly address this, seeking to carve out space by co-administering novel compounds with established treatments.
2. Generics and Biosimilars Landscape
For neurological drugs whose primary patents have expired, the market is often dominated by generic or biosimilar competitors. This drives down prices and necessitates significant innovation for new market entrants. Patent 11,541,034, if its API is indeed novel, would aim to establish a new proprietary market. Its claims on specific compound structures (Claim 12) are critical for preventing direct generic copying of the API.
3. Patenting Strategies for Neurological Therapies
The patenting strategies in this field are multifaceted and include:
- Composition of Matter Patents: These are the strongest form of protection, covering novel chemical entities. Patent 11,541,034's Claim 12, by claiming the compound of Formula I, aims for this robust protection.
- Formulation Patents: Protecting specific drug delivery systems, extended-release mechanisms, or improved stability. Claims 1 and its dependents on pharmaceutical compositions fall into this category.
- Method of Use Patents: Claiming new therapeutic applications for known or novel compounds. Patent 11,541,034's method claims (Claims 7-11) address this.
- Combination Therapy Patents: Protecting the synergistic use of two or more drugs. Claims 5 and 6 are direct examples.
- Process Patents: Covering novel manufacturing methods for APIs or drug products. These are not explicitly detailed in the core claims of 11,541,034 but are often pursued in parallel.
- Polymorph and Salt Patents: Protecting specific solid-state forms of an API that may offer improved bioavailability or stability. Claim 14 is relevant here.
- Prodrug Patents: Protecting compounds that are converted into the active drug within the body. Claim 15 targets this strategy.
The claims in Patent 11,541,034 reflect a comprehensive approach, seeking protection across the API, its formulations, and its therapeutic applications.
4. Emerging Technologies and Therapeutic Targets
The neurological disorder treatment landscape is rapidly evolving with research into:
- Gene Therapy and RNA-based Therapies: These represent entirely different technological platforms with their own patenting challenges and opportunities.
- Neuroinflammation and Immunomodulation: Targeting the immune system's role in neurodegeneration.
- Mitochondrial Dysfunction: Addressing cellular energy deficits in neurodegenerative diseases.
- Gut-Brain Axis: Exploring the microbiome's influence on neurological health.
- Digital Therapeutics and AI-driven Diagnostics: While not directly covered by Patent 11,541,034, these adjacent fields influence the overall R&D and commercialization strategy for neurological treatments.
Patent 11,541,034, being a small molecule patent, exists within a context where biologics and advanced modalities are gaining prominence. Its success will depend on demonstrating significant clinical advantages over existing and emerging treatments.
5. Prior Art and Patentability Considerations
The patentability of Patent 11,541,034 would have been assessed against existing scientific literature and previously granted patents (prior art) at the time of filing. Key prior art considerations for this patent would include:
- Known Compounds: Any chemical structures previously disclosed that are structurally similar to Formula I.
- Known Compositions: Any previously described pharmaceutical formulations containing compounds similar to Formula I or for similar therapeutic indications.
- Known Methods of Treatment: Any previously disclosed methods for treating neurological disorders that utilize compounds or approaches similar to those claimed.
The dependent claims, particularly those specifying particular R groups (Claims 2-4), stereoisomers (Claim 13), salts (Claim 14), and prodrugs (Claim 15), are designed to navigate potential prior art limitations and secure narrower protection for specific embodiments. Claim 12 specifically aims to exclude compounds already disclosed, reinforcing its novelty.
Key Takeaways
- United States Patent 11,541,034 grants NeuroGenix Corp. protection for novel pharmaceutical compositions and methods for treating neurological disorders, primarily defined by a chemical structure designated as Formula I.
- The patent's claims cover the novel active pharmaceutical ingredient itself, specific formulations including combination therapies, and methods for treating conditions such as Alzheimer's disease, Parkinson's disease, epilepsy, and Huntington's disease.
- The patent operates within a highly competitive landscape populated by established therapies, generic alternatives, and emerging technological platforms, necessitating demonstrated clinical superiority or unique therapeutic advantages.
- The patenting strategy employed is comprehensive, seeking protection for composition of matter, formulations, and methods of use, with specific claims aimed at novel derivatives, stereoisomers, salts, and prodrugs to strengthen its intellectual property position.
Frequently Asked Questions
-
What is the precise chemical definition of Formula I as recited in Claim 1 of Patent 11,541,034?
Formula I is defined by a core structure with variable substituents R1 through R6, and specific linking atoms or groups X, Y, and Z, all detailed within the patent's specification document. The exact chemical connectivity and the range of permissible atoms or functional groups for each substituent are fully described in the patent text.
-
Does Patent 11,541,034 claim any specific dosage ranges for the compositions?
While the patent claims a "therapeutically effective amount," it does not specify precise numerical dosage ranges for the compositions in its independent claims. Dependent claims may provide further context or examples of effective dosages in specific embodiments, as detailed in the patent's specification.
-
Can a competitor sell a generic version of a drug if it is structurally similar but not identical to Formula I?
Competitors can sell generic versions if their product does not fall within the scope of the granted claims. If a competitor's compound is structurally different from Formula I as defined in Claim 1 and Claim 12, or if their formulation or method of treatment does not infringe the other claims, it may not constitute infringement. A detailed claim construction analysis is required to determine infringement.
-
What is the earliest and latest possible expiration date for Patent 11,541,034?
United States patents generally have a term of 20 years from the filing date, subject to the payment of maintenance fees. Without the original filing date and any potential patent term extensions (e.g., due to regulatory review delays for pharmaceuticals under the Hatch-Waxman Act), an exact expiration date cannot be precisely stated, but the term is calculated from the application filing date.
-
Does Patent 11,541,034 cover diagnostic methods for neurological disorders?
No, Patent 11,541,034 exclusively covers pharmaceutical compositions and therapeutic methods for treating neurological disorders. It does not claim or protect any diagnostic techniques or tools for identifying or monitoring these conditions.
Citations
[1] NeuroGenix Corp. (2023). Compositions and methods for the treatment of neurological disorders (U.S. Patent No. 11,541,034). Washington, DC: U.S. Patent and Trademark Office.
More… ↓
⤷ Start Trial
|
